IL129938A - A method for formulating a consequence of tetrahydropyridine, a mixture of crystalline forms obtained by this method and pharmaceutical preparations containing this mixture - Google Patents

A method for formulating a consequence of tetrahydropyridine, a mixture of crystalline forms obtained by this method and pharmaceutical preparations containing this mixture

Info

Publication number: IL129938A
Authority: IL; Israel
Prior art keywords: mixture; ethyl; naphthyl; trifluoromethyl; tetrahydropyridine hydrochloride
Prior art date: 1996-12-23

Application number

IL12993897A

Other languages

English (en)

Hebrew (he)

Other versions

IL129938A0 (en

Original Assignee

Sanofi Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-23

Filing date

1997-12-23

Publication date

2004-06-20

1997-12-23 Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo

2000-02-29 Publication of IL129938A0 publication Critical patent/IL129938A0/xx

2004-06-20 Publication of IL129938A publication Critical patent/IL129938A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 76
238000000034 method Methods 0.000 title claims abstract description 29
239000008194 pharmaceutical composition Substances 0.000 title claims description 13
238000002425 crystallisation Methods 0.000 title description 7
230000008025 crystallization Effects 0.000 title description 7
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title description 4
WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 claims abstract description 71
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
238000004090 dissolution Methods 0.000 claims abstract description 16
150000001875 compounds Chemical class 0.000 claims abstract description 5
WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 claims abstract 3
238000001816 cooling Methods 0.000 claims description 30
125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 27
230000007704 transition Effects 0.000 claims description 26
239000007787 solid Substances 0.000 claims description 15
HAKSOKWVNPZVNM-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridine;hydrochloride Chemical compound Cl.C1CNC=CC1 HAKSOKWVNPZVNM-UHFFFAOYSA-N 0.000 claims description 13
239000012458 free base Substances 0.000 claims description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
239000000047 product Substances 0.000 description 26
238000003756 stirring Methods 0.000 description 19
238000001757 thermogravimetry curve Methods 0.000 description 18
238000002360 preparation method Methods 0.000 description 16
238000000113 differential scanning calorimetry Methods 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
239000002245 particle Substances 0.000 description 8
238000010992 reflux Methods 0.000 description 8
239000002904 solvent Substances 0.000 description 8
238000000634 powder X-ray diffraction Methods 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 6
239000013078 crystal Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000035699 permeability Effects 0.000 description 3
230000007928 solubilization Effects 0.000 description 3
238000005063 solubilization Methods 0.000 description 3
-1 3-trifluoromethylphenyl Chemical group 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
241000894007 species Species 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229940124332 anorexigenic agent Drugs 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
229940064452 artec Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
229940045200 cardioprotective agent Drugs 0.000 description 1
239000012659 cardioprotective agent Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
238000009602 toxicology test Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Nutrition Science (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL12993897A 1996-12-23 1997-12-23 A method for formulating a consequence of tetrahydropyridine, a mixture of crystalline forms obtained by this method and pharmaceutical preparations containing this mixture IL129938A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9615904A FR2757543B1 (fr)	1996-12-23	1996-12-23	Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
PCT/FR1997/002393 WO1998028271A1 (fr)	1996-12-23	1997-12-23	Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (2)

Publication Number	Publication Date
IL129938A0 IL129938A0 (en)	2000-02-29
IL129938A true IL129938A (en)	2004-06-20

Family

ID=9499043

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12993897A IL129938A (en)	1996-12-23	1997-12-23	A method for formulating a consequence of tetrahydropyridine, a mixture of crystalline forms obtained by this method and pharmaceutical preparations containing this mixture

Country Status (38)

Country	Link
EP (1)	EP0950050B1 (sr)
JP (2)	JP4499188B2 (sr)
KR (1)	KR100586670B1 (sr)
CN (1)	CN1129580C (sr)
AR (1)	AR009672A1 (sr)
AT (1)	ATE307802T1 (sr)
AU (1)	AU736697B2 (sr)
BR (1)	BR9714081A (sr)
CA (1)	CA2275596C (sr)
CO (1)	CO5070688A1 (sr)
CZ (1)	CZ296689B6 (sr)
DE (1)	DE69734460T2 (sr)
DK (1)	DK0950050T3 (sr)
DZ (1)	DZ2383A1 (sr)
EE (1)	EE04188B1 (sr)
EG (1)	EG21567A (sr)
ES (1)	ES2251038T3 (sr)
FR (1)	FR2757543B1 (sr)
HR (1)	HRP970699B1 (sr)
HU (1)	HU227425B1 (sr)
IL (1)	IL129938A (sr)
IN (1)	IN186976B (sr)
IS (1)	IS2357B (sr)
MY (1)	MY118015A (sr)
NO (1)	NO312364B1 (sr)
NZ (1)	NZ336130A (sr)
PL (1)	PL190494B1 (sr)
RS (1)	RS49882B (sr)
RU (1)	RU2192416C2 (sr)
SA (1)	SA98180971B1 (sr)
SI (1)	SI0950050T1 (sr)
SK (1)	SK285088B6 (sr)
TR (1)	TR199901363T2 (sr)
TW (1)	TW518322B (sr)
UA (1)	UA60324C2 (sr)
UY (1)	UY24825A1 (sr)
WO (1)	WO1998028271A1 (sr)
ZA (1)	ZA9711576B (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2757543B1 (fr) *	1996-12-23	1999-04-02	Sanofi Sa	Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) *	1998-08-05	2000-09-22	Sanofi Sa	Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
WO2011111857A1 (ja)	2010-03-12	2011-09-15	株式会社日本触媒	吸水性樹脂の製造方法
AP2013006779A0 (en) *	2011-04-15	2013-03-31	Emcure Pharmaceuticals Ltd	An improved rilpivirine process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2531707A1 (fr) *	1982-08-16	1984-02-17	Midy Spa	Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) *	1996-12-23	1999-04-02	Sanofi Sa	Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

1996
- 1996-12-23 FR FR9615904A patent/FR2757543B1/fr not_active Expired - Fee Related
1997
- 1997-12-19 AR ARP970106029A patent/AR009672A1/es not_active Application Discontinuation
- 1997-12-22 MY MYPI97006233A patent/MY118015A/en unknown
- 1997-12-22 HR HR970699A patent/HRP970699B1/xx not_active IP Right Cessation
- 1997-12-22 DZ DZ970233A patent/DZ2383A1/xx active
- 1997-12-23 SK SK828-99A patent/SK285088B6/sk not_active IP Right Cessation
- 1997-12-23 ZA ZA9711576A patent/ZA9711576B/xx unknown
- 1997-12-23 DE DE69734460T patent/DE69734460T2/de not_active Expired - Lifetime
- 1997-12-23 AT AT97952986T patent/ATE307802T1/de active
- 1997-12-23 SI SI9730720T patent/SI0950050T1/sl unknown
- 1997-12-23 RU RU99116597/04A patent/RU2192416C2/ru not_active IP Right Cessation
- 1997-12-23 EP EP97952986A patent/EP0950050B1/fr not_active Expired - Lifetime
- 1997-12-23 HU HU0001387A patent/HU227425B1/hu not_active IP Right Cessation
- 1997-12-23 KR KR1019997005373A patent/KR100586670B1/ko not_active Expired - Fee Related
- 1997-12-23 IL IL12993897A patent/IL129938A/en not_active IP Right Cessation
- 1997-12-23 NZ NZ336130A patent/NZ336130A/xx not_active IP Right Cessation
- 1997-12-23 IN IN3761DE1997 patent/IN186976B/en unknown
- 1997-12-23 UA UA99063521A patent/UA60324C2/uk unknown
- 1997-12-23 RS YUP-289/99A patent/RS49882B/sr unknown
- 1997-12-23 CA CA002275596A patent/CA2275596C/en not_active Expired - Fee Related
- 1997-12-23 BR BR9714081-3A patent/BR9714081A/pt not_active Application Discontinuation
- 1997-12-23 AU AU56684/98A patent/AU736697B2/en not_active Ceased
- 1997-12-23 JP JP52848198A patent/JP4499188B2/ja not_active Expired - Fee Related
- 1997-12-23 DK DK97952986T patent/DK0950050T3/da active
- 1997-12-23 CN CN97180863A patent/CN1129580C/zh not_active Expired - Fee Related
- 1997-12-23 EG EG138397A patent/EG21567A/xx active
- 1997-12-23 UY UY24825A patent/UY24825A1/es not_active IP Right Cessation
- 1997-12-23 CZ CZ0229299A patent/CZ296689B6/cs not_active IP Right Cessation
- 1997-12-23 WO PCT/FR1997/002393 patent/WO1998028271A1/fr not_active Ceased
- 1997-12-23 TR TR1999/01363T patent/TR199901363T2/xx unknown
- 1997-12-23 ES ES97952986T patent/ES2251038T3/es not_active Expired - Lifetime
- 1997-12-23 CO CO97074792A patent/CO5070688A1/es unknown
- 1997-12-23 PL PL97334256A patent/PL190494B1/pl not_active IP Right Cessation
- 1997-12-23 EE EEP199900264A patent/EE04188B1/xx not_active IP Right Cessation
1998
- 1998-01-21 TW TW086119629A patent/TW518322B/zh not_active IP Right Cessation
- 1998-03-11 SA SA98180971A patent/SA98180971B1/ar unknown
1999
- 1999-06-10 IS IS5076A patent/IS2357B/is unknown
- 1999-06-22 NO NO19993076A patent/NO312364B1/no not_active IP Right Cessation
2009
- 2009-05-07 JP JP2009112971A patent/JP2009197022A/ja active Pending

Also Published As

Publication number	Publication date
DK0950050T3 (da)	2006-01-23
DE69734460D1 (de)	2005-12-01
DZ2383A1 (fr)	2002-12-28
UA60324C2 (uk)	2003-10-15
PL190494B1 (pl)	2005-12-30
TW518322B (en)	2003-01-21
DE69734460T2 (de)	2006-07-06
SK285088B6 (sk)	2006-06-01
HU227425B1 (en)	2011-05-30
IL129938A0 (en)	2000-02-29
CN1129580C (zh)	2003-12-03
BR9714081A (pt)	2000-05-09
KR100586670B1 (ko)	2006-06-07
ES2251038T3 (es)	2006-04-16
IN186976B (sr)	2001-12-22
AU5668498A (en)	1998-07-17
YU28999A (sh)	2003-01-31
SK82899A3 (en)	1999-12-10
FR2757543A1 (fr)	1998-06-26
KR20000069504A (ko)	2000-11-25
MY118015A (en)	2004-08-30
UY24825A1 (es)	1998-04-21
WO1998028271A1 (fr)	1998-07-02
HUP0001387A2 (hu)	2000-09-28
ZA9711576B (en)	1998-06-25
IS2357B (is)	2008-04-15
NO312364B1 (no)	2002-04-29
PL334256A1 (en)	2000-02-14
AR009672A1 (es)	2000-04-26
NO993076L (no)	1999-06-22
TR199901363T2 (xx)	1999-08-23
EP0950050A1 (fr)	1999-10-20
HUP0001387A3 (en)	2002-03-28
ATE307802T1 (de)	2005-11-15
EP0950050B1 (fr)	2005-10-26
EG21567A (en)	2001-12-31
SI0950050T1 (sl)	2006-04-30
HRP970699A2 (en)	1998-10-31
CO5070688A1 (es)	2001-08-28
HRP970699B1 (en)	2007-03-31
JP2009197022A (ja)	2009-09-03
FR2757543B1 (fr)	1999-04-02
IS5076A (is)	1999-06-10
NZ336130A (en)	2001-01-26
EE04188B1 (et)	2003-12-15
JP2001507012A (ja)	2001-05-29
CN1241180A (zh)	2000-01-12
CA2275596C (en)	2005-10-11
NO993076D0 (no)	1999-06-22
SA98180971B1 (ar)	2006-09-13
CZ296689B6 (cs)	2006-05-17
EE9900264A (et)	2000-02-15
HK1024002A1 (en)	2000-09-29
RU2192416C2 (ru)	2002-11-10
AU736697B2 (en)	2001-08-02
RS49882B (sr)	2008-08-07
CA2275596A1 (en)	1998-07-02
CZ229299A3 (cs)	1999-09-15
JP4499188B2 (ja)	2010-07-07

Legal Events

Date	Code	Title
2004-11-24	FF	Patent granted
2005-02-20	KB	Patent renewed
2008-01-22	KB	Patent renewed
2011-12-29	KB	Patent renewed
2016-07-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
JP2009102345A (ja)	2009-05-14	結晶性ジベンゾチアゼピン誘導体およびその抗精神病薬としての使用
WO2011050962A1 (en)	2011-05-05	Acid addition salts of lenalidomide
CA2275596C (en)	2005-10-11	Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms
US6489334B2 (en)	2002-12-03	Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
JPH05229945A (ja)	1993-09-07	特定の結晶変態を有する１，４−ジヒドロ−２，６−ジメチル−４−（３−ニトロフエニル）−３，５−ピリジンジカルボン酸イソプロピル−（２−メトキシエチル）を含有する薬学的調製物
JP2009280581A (ja)	2009-12-03	テトラヒドロピリジン誘導体の微粒子形態
AU612344B2 (en)	1991-07-11	- 8-heterocyclo-ergoline derivatives useful in the treatment of extrapyramidal syndromes
MXPA99005620A (en)	2000-05-01	Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms
CZ211399A3 (cs)	2000-09-13	1-fenylalkyl-1,2,3,6-tetrahydropyridiny pro léčení Alzheimerovy choroby
EP1858847A1 (en)	2007-11-28	Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
MXPA99005621A (en)	2000-05-01	Micro-particulate form of a tetrahydropyridin derivative
WO2003042161A1 (en)	2003-05-22	Venlafaxine hydrochloride polymorphs
HRP970701A2 (en)	1998-10-31	Micro-particulate form of a tetrahydropyridin derivative
MXPA00010435A (en)	2001-07-31	Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA99005108A (en)	2000-06-01	1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating alzheimer's disease
MXPA00009884A (en)	2001-12-13	Paroxetine maleate